Research programme: gene therapies - Precision Biosciences
Latest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator Precision Biosciences
- Class Antihyperlipidaemics; Endodeoxyribonucleases; Enzymes; Eye disorder therapies; Gene therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Transthyretin-related hereditary amyloidosis
- No development reported Amyloid polyneuropathy; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa; Retinitis pigmentosa
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Hyperlipoproteinaemia-type-I in USA (Parenteral)
- 28 Mar 2024 No recent reports of development identified for research development in Hyperlipoproteinaemia-type-IIa in USA (Parenteral)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Amyloid polyneuropathy in USA (Parenteral)